IFN-α has been approved for the treatment of several types of cancer, including:
- Melanoma: Particularly for high-risk patients as adjuvant therapy to prevent recurrence. - Chronic Myeloid Leukemia (CML): Used before the advent of tyrosine kinase inhibitors. - Hairy Cell Leukemia: One of the first cancers to show significant response to IFN-α. - Renal Cell Carcinoma: Sometimes used in combination with other agents. - Kaposi's Sarcoma: Especially in patients with AIDS-related Kaposi's Sarcoma.
